First, a predicted glut; now, an apparent shortage. Getting physician supply to match demand is hard; getting it wrong could be devastating.
Marianne J. Legato, founder of the field of gender-specific medicine, is only beginning to uncover how different the sexes are.
As more of us choose a different way to die, a philosophy has become an industry, raising questions about access, quality—and profits.
Disgraced stem-cell scientist Woo Suk Hwang has become exhibit A in the case for tightening scrutiny of apparent medical advances.
Transplant surgeon Amy Friedman argues: Since we can’t get enough organs for free, why not pay for them?
As today’s caregivers face a rainbow of cultures, issues of race, religion and language can make or break a treatment plan.
The testing of artificial blood has sparked controversy over individual rights.
Television portrays ERs as high-tech places where everyone gets saved. But what’s the real deal?
Pay for performance seems simple: Give doctors financial incentives to improve care. So what’s taking so long?
No-name drugs may be cheaper than brand names, but they have some drawbacks as well.
No Articles Found.
Stay on the frontiers of medicine